Aurobindo Pharma has received final USFDA approval to manufacture and market pantoprazole sodium for injections, used for the treatment of gastroesophageal reflux disease, in the American market. The approved ANDA (Abbreviated New Drug Applications) is bioequivalent and therapeutically equivalent to the reference listed drug product Protonix I.V. for injection, 40 mg/vial for Wyeth Pharmaceuticals. The drug pantoprazole has an estimated market size of USD 93.5 million for the twelve months ending February 2016. Pantoprazole sodium for injections is a gastrointestinal drug used in the treatment of gastroesophageal reflux disease.
Company Profile : Aurobindo Pharma Ltd
Leave a Reply